Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more
Vivoryon Therapeutics N.V. (0R3M) - Total Assets
Latest total assets as of June 2025: €6.42 Million EUR
Based on the latest financial reports, Vivoryon Therapeutics N.V. (0R3M) holds total assets worth €6.42 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vivoryon Therapeutics N.V. - Total Assets Trend (2010–2024)
This chart illustrates how Vivoryon Therapeutics N.V.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vivoryon Therapeutics N.V. - Asset Composition Analysis
Current Asset Composition (December 2024)
Vivoryon Therapeutics N.V.'s total assets of €6.42 Million consist of 89.2% current assets and 10.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 83.0% |
| Accounts Receivable | €312.00K | 2.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €865.00K | 7.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Vivoryon Therapeutics N.V.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vivoryon Therapeutics N.V.'s current assets represent 89.2% of total assets in 2024, an increase from 47.5% in 2010.
- Cash Position: Cash and equivalents constituted 83.0% of total assets in 2024, up from 38.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 42.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 7.7% of total assets.
Vivoryon Therapeutics N.V. Competitors by Total Assets
Key competitors of Vivoryon Therapeutics N.V. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Vivoryon Therapeutics N.V. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Vivoryon Therapeutics N.V. generates -0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Vivoryon Therapeutics N.V. is currently not profitable relative to its asset base.
Vivoryon Therapeutics N.V. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.04 | 9.37 | 56.68 |
| Quick Ratio | 4.04 | 9.37 | 56.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.94 Million | € 14.34 Million | € 34.30 Million |
Vivoryon Therapeutics N.V. - Advanced Valuation Insights
This section examines the relationship between Vivoryon Therapeutics N.V.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 1.80 |
| Asset Growth Rate (YoY) | -63.4% |
| Total Assets | €11.28 Million |
| Market Capitalization | $20.35 Million USD |
Valuation Analysis
Above Book Valuation: The market values Vivoryon Therapeutics N.V.'s assets above their book value (1.80 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Vivoryon Therapeutics N.V.'s assets decreased by 63.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vivoryon Therapeutics N.V. (2010–2024)
The table below shows the annual total assets of Vivoryon Therapeutics N.V. from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €11.28 Million | -63.40% |
| 2023-12-31 | €30.83 Million | -1.75% |
| 2022-12-31 | €31.38 Million | +27.97% |
| 2021-12-31 | €24.52 Million | -17.58% |
| 2020-12-31 | €29.75 Million | -35.13% |
| 2019-12-31 | €45.86 Million | +1132829.84% |
| 2018-12-31 | €4.05K | -62.39% |
| 2017-12-31 | €10.76K | -51.88% |
| 2016-12-31 | €22.37K | +2.29% |
| 2015-12-31 | €21.87K | +1.80% |
| 2014-12-31 | €21.48K | -99.66% |
| 2013-12-31 | €6.37 Million | -36.29% |
| 2012-12-31 | €10.01 Million | -47.60% |
| 2011-12-31 | €19.09 Million | +19.59% |
| 2010-12-31 | €15.97 Million | -- |